GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NVN Liquidation Inc (OTCPK:NOVNQ) » Definitions » ROE %
中文

NVN Liquidation (NVN Liquidation) ROE % : -6,356.33% (As of Mar. 2023)


View and export this data going back to 2016. Start your Free Trial

What is NVN Liquidation ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NVN Liquidation's annualized net income for the quarter that ended in Mar. 2023 was $-56.48 Mil. NVN Liquidation's average Total Stockholders Equity over the quarter that ended in Mar. 2023 was $0.89 Mil. Therefore, NVN Liquidation's annualized ROE % for the quarter that ended in Mar. 2023 was -6,356.33%.

The historical rank and industry rank for NVN Liquidation's ROE % or its related term are showing as below:

NOVNQ's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.08
* Ranked among companies with meaningful ROE % only.

NVN Liquidation ROE % Historical Data

The historical data trend for NVN Liquidation's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NVN Liquidation ROE % Chart

NVN Liquidation Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only -1,238.42 - - -278.85 -273.17

NVN Liquidation Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -442.30 -391.73 -253.77 -212.79 -6,356.33

Competitive Comparison of NVN Liquidation's ROE %

For the Biotechnology subindustry, NVN Liquidation's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NVN Liquidation's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NVN Liquidation's ROE % distribution charts can be found below:

* The bar in red indicates where NVN Liquidation's ROE % falls into.



NVN Liquidation ROE % Calculation

NVN Liquidation's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-31.311/( (18.319+4.605)/ 2 )
=-31.311/11.462
=-273.17 %

NVN Liquidation's annualized ROE % for the quarter that ended in Mar. 2023 is calculated as

ROE %=Net Income (Q: Mar. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Mar. 2023 ))/ count )
=-56.476/( (4.605+-2.828)/ 2 )
=-56.476/0.8885
=-6,356.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2023) net income data. ROE % is displayed in the 30-year financial page.


NVN Liquidation  (OTCPK:NOVNQ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-56.476/0.8885
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-56.476 / 11.984)*(11.984 / 85.0615)*(85.0615 / 0.8885)
=Net Margin %*Asset Turnover*Equity Multiplier
=-471.26 %*0.1409*95.7361
=ROA %*Equity Multiplier
=-66.4 %*95.7361
=-6,356.33 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=-56.476/0.8885
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-56.476 / -56.252) * (-56.252 / -53.872) * (-53.872 / 11.984) * (11.984 / 85.0615) * (85.0615 / 0.8885)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.004 * 1.0442 * -449.53 % * 0.1409 * 95.7361
=-6,356.33 %

Note: The net income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NVN Liquidation ROE % Related Terms

Thank you for viewing the detailed overview of NVN Liquidation's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NVN Liquidation (NVN Liquidation) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 64, Pittsboro, NC, USA, 27312
NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James L Bierman director 9120 LOCKWOOD BOULEVARD, MECHANICSVILLE VA 23116
John W Palmour director C/O CREE, INC., 4600 SILICON DRIVE, DURHAM NC 27703
John M. Gay officer: VP, Finance & Corp. Controller C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
A. Donofrio John officer: EVP, Chief Operating Officer C/O NOVAN, INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM NC 27703
Paula B Stafford director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Steven D Skolsky director TRIMERIS, INC., 3500 PARAMOUNT PARKWAY, MORRISVILLE NC 27560
Malin Life Sciences Holdings Ltd 10 percent owner 2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
G. Kelly Martin director C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Robert Alexander Ingram director 280 S. MANGUM STREET, SUITE 350, DURHAM NC 27701
W Kent Geer director 7104 RAINWATER ROAD, RALEIGH NC 27615
Andrew Novak officer: Chief Accounting Officer C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Eugene Sun director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
James H. Goodnight Management Trust 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513
Donald R Parker 10 percent owner 100 SAS CAMPUS DRIVE, CARY NC 27513